Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 1—January 2005
Research

Demand for Prophylaxis after Bioterrorism-Related Anthrax Cases, 2001

Edward A. Belongia*Comments to Author , Burney Kieke*, Ruth Lynfield†, Jeffrey P. Davis‡, and Richard E. Besser§
Author affiliations: *Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; †Minnesota Department of Health, Minneapolis, Minnesota, USA; ‡Wisconsin Division of Public Health, Madison, Wisconsin, USA; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 2

A) Retail distribution of fluoroquinolone antimicrobial agents, January 1999 through December 2002. Volume was measured in kilograms. B) Actual and predicted retail distribution of fluoroquinolone antimicrobial agents as a percentage of total antibiotic volume distribution (excluding tetracyclines), January 1999 through December 2002. Vertical bars show 95% confidence intervals.

Figure 2. A) Retail distribution of fluoroquinolone antimicrobial agents, January 1999 through December 2002. Volume was measured in kilograms. B) Actual and predicted retail distribution of fluoroquinolone antimicrobial agents as a percentage of total antibiotic volume distribution (excluding tetracyclines), January 1999 through December 2002. Vertical bars show 95% confidence intervals.

Main Article

Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external